Compass Therapeutics Inc.’s Post

We’ve nominated the first candidate from our proprietary pipeline of novel immunometabolism-targeting therapies – the oral, targeted pyruvate kinase M2 (PKM2) activator, SYX-5219 – for clinical development.   SYX-5219 offers first-in-class potential as a disease-modifying, anti-inflammatory therapy for atopic dermatitis, the most common inflammatory skin disease.   Regulatory submission preparation for SYX-5219 is underway, with clinical trials expected to commence in early 2025.   Learn more here: https://lnkd.in/eS8FGNRx   #CellMetabolism #DrugDiscovery #DrugDevelopment #Immunometabolism #Biotechnology #Biotech

Webinar now available on demand! Better mRNA-LNPs: encapsulation efficiency, #mRNA integrity and purity, lipid N-oxides, and beyond In this webinar, Jane Luo (Senior Scientist, SCIEX) explores the analytical challenges associated with characterizing mRNA-LNPs, including distinguishing harmful N-oxides from other oxidation products and assessing LNP encapsulation efficiency, integrity, purity, and stability of in vitro transcribed #RNA. Watch this webinar to: • Learn why process-related #lipid impurities are a concern for therapeutics and vaccines • Discover how to achieve detailed structural characterization of ionizable lipids and their impurities, using the ionizable lipid ALC-0315 as an example • Explore how to break through limitations of intact mRNA analysis • Take control of determining mRNA-LNP encapsulation efficiency Watch this #webinar at your convenience below:

Noninvasive urine-based biomarker testing can support routine testing for graft dysfunction WEST HILLS, Calif.--(BUSINESS WIRE)-- For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of rejection, both of which may carry complications. Now, a simple, urine-based assay that detects the CXCL10 chemokine may make care more convenient and less invasive for the nearly 250,000 Americans living with a k... https://buff.ly/3UoPsMe Noninvasive urine-based biomarker testing can support routine testing for graft dysfunction WEST HILLS, Calif.--(BUSINESS WIRE)-- For organ transplant recipients, life post-transplant involves a delicate balance between invasive monitoring and immunosuppression to reduce the risk of rejection, both of which may carry complications. Now, a simple, urine-based assay that detects the CXCL10 chemokine may make care more convenient and less invasive for the nearly 250,000 Americans living with a k... #pharma #biotech #lifesciences #clinicalresearch #news #pharmiweb

Single domain antibodies are small, antigen-binding fragments derived from naturally occurring heavy-chain antibodies found in camelids, such as llamas and camels. Unlike conventional antibodies, which consist of two heavy chains and two light chains, single domain antibodies comprise a single, compact domain that retains high specificity and affinity for their target antigen. This unique structural feature confers several advantages, including superior stability, solubility, and tissue penetration, making them attractive candidates for therapeutic intervention. https://lnkd.in/gUXK-y4J #SingleDomainAntibodies #CamelidAntibodies #LlamaAntibodies #CamelAntibodies #Biotechnology #ImmunoTherapy #Bioengineering #AlphaLifeTech #BioTechCompany #DomainLibraryConstruction #TherapeuticCandidates

😃 Expanding the GPCR-RAMP Interactome with MolBoolean The GPCR-RAMP interactome is important for understanding G protein-coupled receptors (GPCRs) function, drug discovery, disease mechanisms, and personalized medicine. 👉🏼 In a new study, Kotliar et al, used the #MolBoolean assay from #AtlasAntibodies to test for native GPCR-RAMP complexes in cell membranes. They specifically investigated GPCR-RAMP2 interactions in SK-N-MC cells. The results of the MolBoolean assay showed that several GPCRs exhibited complex formation with RAMP2, such as the presence of GPCR-RAMP2 complexes in the cell membranes. Overall, the MolBoolean assay provided evidence for the physiological relevance of GPCR-RAMP interactions and confirmed the presence of GPCR-RAMP2 complexes in native cell membranes. 👉🏼 Read full article here: https://ow.ly/qgcf50SkNrH 👉🏼 Learn more about MolBoolean: https://lnkd.in/dAFePfmk #insituPLA #antibodies #proteomic #GPCRs

#AntibodyDrugConjugates (ADCs) differ from #radiopharmaceuticals regarding one important mechanistic aspect: They need to be internalized by the target cell to have the toxic payload take effect. How can #DARPinDrugConjugates (DDCs) help in that space?   Effective treatment with drug conjugates requires that the toxin is released inside of the cells.   The first step in this mechanism is the clustering of receptors on the cell surface that triggers the formation of endosomes, which will include any receptor-bound drug conjugates. Inside the cells, the endosomes may then fuse with lysosomes and become degraded, thus releasing the toxin, or simply recycle back to the cell surface without releasing the toxin.   Think of it as a revolving door: To get beyond it, you must not stay for a full round but exit on the opposite side of it. Similarly, an effective #DrugConjugate should not ride a full round of receptor recycling, but ideally exit the carousel inside the cell.   Clustering the targeted receptor molecules with #mAbs or #DARPins – the binding moieties of ADCs or DDCs - can facilitate this process. One publication that nicely illustrates this effect for DARPins is a study on EGFR-binding DARPins by Ykelien L. Boersma et al. (https://lnkd.in/efKfHFZB): By combining DARPin domains recognizing two different epitopes on #EGFR, a bispecific, tetravalent DARPin was created that significantly inhibits receptor recycling, so that more EGFR ended up in lysosomes and stayed inside the cells. Finding the perfect DrugConjugate that replicates such effect will always be a matter of testing different epitopes, affinities, valencies and binding geometries.   The plug & play versatility of the #DARPin technology helps to make that discovery process more efficient, thus holding great promise for the future development of DDCs.     #Athebio  #drugdevelopment

In the field of biotherapeutics, two significant obstacles—lengthy development processes and underperforming therapies—hinder progress and restrict treatment effectiveness. To overcome these challenges, we have developed two innovative solutions designed to transform the industry. One of them is Opti-mAb™ – a new scFv format with dramatically improved expression levels and reduced aggregation tendencies. This will significantly improve the next generation of cutting-edge immunotherapies such as CAR-T and bispecific antibodies. Visit our website to learn more about Opti-mAb™: https://lnkd.in/dGmH3AyF #Biotech #AntibodyTherapeutics #NextGenTherapeutics

🎉🧬 Celebrating Two Decades of Progress in Nucleic Acid Therapeutics! Thanks to the invaluable insights from the #OTS2023 Meeting, NATA is thrilled to share a significant milestone in the world of Nucleic Acid Therapy. 👏 From 1998 to 2023, we have witnessed 21 approved Nucleic Acid Therapeutics (#NATs), marking a groundbreaking era of progress and an exciting future for this transformative field. At NATA, our mission is to accelerate the translation of NATs into real-world applications through interdisciplinary collaboration. The knowledge and innovative spirit displayed at the #OTS Meeting have only reaffirmed the potential of NATs to revolutionise medicine. These 21 approvals represent not just scientific achievements but also reflect the dedication of researchers, scientists, and the entire healthcare industry. 🚀 As we look ahead, NATA will remain committed to our goal of fostering collaboration, innovation, and translation in the NAT field. The promise of NATs in treating a wide range of diseases and conditions is more vibrant than ever, and we're excited for a bright future in the world of healthcare. Oligonucleotide Therapeutics Society #OligoMeeting #OTS23 #OTSMeeting #OligonucleotideTherapeuticsSociety #NATA #Research #science #oligonucleotides #oligonucleotidetherapies #oligonucleotidestherapeutics #oligotherapeutics #oligo #pharma #pharamaceutical #RNAdelivery #RNAtherapeutics #RNAdelivery #RNAtherapies #therapeutics #drugdiscovery #biotech #biotechnology #AdvancedTherapies #GlobalHealth #RareDiseases #NATs #Healthcare #Impact #Industry #Innovation #AdvancedTherapies #biochem #Biomedical #biopharma #biotech #biotechnology #clinicalresearch #drugdesign #drugdevelopment #drugdiscovery #genomics #GeneTherapy #health #HealthcareInnovation #LifeScience #Medicine #PrecisionMedicine #RareDisease #nucleotides

We welcome the new additions to the list of approved therapeutic oligonucleotides: ZIMURA (avacincaptad pegol) and RIVFLOZA (nedosiran) Thanks for the post of this page - thanks for NATA for this update on approved Nucleic Acid Therapeutics #Kilobaser #DNAonDemand #rnatherapeutics #OligonucleotideTherapeutics

Single domain antibodies are small, antigen-binding fragments derived from naturally occurring heavy-chain antibodies found in camelids, such as llamas and camels. Unlike conventional antibodies, which consist of two heavy chains and two light chains, single domain antibodies comprise a single, compact domain that retains high specificity and affinity for their target antigen. This unique structural feature confers several advantages, including superior stability, solubility, and tissue penetration, making them attractive candidates for therapeutic intervention. https://lnkd.in/gXY8y7wu #SingleDomainAntibodies #CamelidAntibodies #LlamaAntibodies #CamelAntibodies #Biotechnology #ImmunoTherapy #Bioengineering #AlphaLifeTech #BioTechCompany #DomainLibraryConstruction #TherapeuticCandidates